Akuru Pharma Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Akuru Pharma General Information

Description

Developer of a bioinformatics platform designed to develop novel diagnostic and treatment modalities. The company's platform is used for the identification of novel surface molecules that can serve as biomarkers for kidney cancer, with a particular focus on transporter proteins, and can be utilized for both diagnostic and therapeutic purposes, thereby enabling doctors to develop novel diagnostic and treatment modalities and find an effective treatment for kidney cancer.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Lilla Algatan 9B
  • 223 50 Lund
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Corporate Office
  • Lilla Algatan 9B
  • 223 50 Lund
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akuru Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 03-Nov-2020 Completed Out of Business
5. Grant 27-Oct-2017 Completed Generating Revenue
4. Accelerator/Incubator 01-Jun-2017 Completed Generating Revenue
3. Early Stage VC 15-Nov-2016 Completed Generating Revenue
2. Accelerator/Incubator 11-Jun-2016 Completed Generating Revenue
1. University Spin-Out 01-Jan-2016 Completed Startup
To view Akuru Pharma’s complete valuation and funding history, request access »

Akuru Pharma Patents

Akuru Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016294377-A1 Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group Inactive 16-Jul-2015
CA-2989507-A1 Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group Inactive 16-Jul-2015
EP-3322450-A1 Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group Inactive 16-Jul-2015
US-20180200392-A1 Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group Inactive 16-Jul-2015
WO-2017009084-A1 Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group Inactive 16-Jul-2015 A61K51/0448
To view Akuru Pharma’s complete patent history, request access »

Akuru Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akuru Pharma FAQs

  • When was Akuru Pharma founded?

    Akuru Pharma was founded in 2016.

  • Where is Akuru Pharma headquartered?

    Akuru Pharma is headquartered in Lund, Sweden.

  • What is the size of Akuru Pharma?

    Akuru Pharma has 3 total employees.

  • What industry is Akuru Pharma in?

    Akuru Pharma’s primary industry is Drug Discovery.

  • Is Akuru Pharma a private or public company?

    Akuru Pharma is a Private company.

  • What is Akuru Pharma’s current revenue?

    The current revenue for Akuru Pharma is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process